The doctor diagnosed him with
lymphoma.
医生诊断他患有淋巴瘤。
Lymphoma is a type of cancer that affects the lymphatic system.
淋巴瘤是一种影响淋巴系统的癌症。
She underwent chemotherapy for her non-Hodgkin's
lymphoma.
她接受了非霍奇金淋巴瘤的化疗。
Hodgkin's
lymphoma is a rare form of cancer that affects the lymph nodes.
霍奇金淋巴瘤是一种罕见的淋巴结癌。
He was in remission from his
lymphoma for several years.
他的淋巴瘤已经缓解了几年。
The symptoms of
lymphoma can include swollen lymph nodes, fatigue, and weight loss.
淋巴瘤的症状可能包括淋巴结肿大、疲劳和体重减轻。
A biopsy confirmed that the lump was indeed
lymphoma.
活组织检查确认肿块确实是淋巴瘤。
The patient is currently undergoing radiation therapy for his aggressive form of
lymphoma.
这位患者目前正在接受其侵袭性淋巴瘤的放射治疗。
Early detection and treatment are key to improving outcomes for patients with
lymphoma.
早期发现和治疗是改善淋巴瘤患者预后的关键。
There are over 60 different types of
lymphoma, each with its own unique characteristics and treatments.
有超过60种不同的淋巴瘤，每种都有其独特的特性和治疗方法。
"So far, the drug has covered major cancer types, including lymphoma, lung cancer, liver cancer, esophageal cancer and gastric cancer, benefiting millions of Chinese patients," he said.
他说：“到目前为止，该药物已涵盖主要的癌症类型，包括淋巴瘤、癌症、癌症、食管癌症和癌症，使数百万中国患者受益。”。
Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
中国生物技术企业百济基因周一宣布，其癌症治疗药物Brukinsa（zanubrutinib）已获得科威特、巴林和卡塔尔当局的批准，用于治疗至少接受过一次治疗的成年套细胞淋巴瘤患者。
In November 2019, Brukinsa was approved by the US Food and Drug Administration to treat mantle cell lymphoma in adult patients, marking the first cancer treatment developed in China to be approved for the US market.
2019年11月，Brukinsa获得美国食品药品监督管理局批准，用于治疗成年患者的套细胞淋巴瘤，这标志着中国开发的第一种癌症治疗方法获准进入美国市场。
Biopharmaceutical companyxa0Pfizer announced on Friday that Lorbrena, the world's first third-generation anaplastic lymphoma kinase inhibitor, has been approved by China's National Medical Products Administration for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
生物制药公司xa0Pfizer周五宣布，世界上第一种第三代间变性淋巴瘤激酶抑制剂Lorbrena已被中国国家药品监督管理局批准用于治疗ALK阳性的局部晚期或转移性癌症患者。
Through this collaboration, Roche Pharma China will further enrich the hematology portfolio, expand the panorama of lymphoma treatment and continue to work together to promote the standardization of lymphoma treatment in China.
通过此次合作，罗氏制药中国公司将进一步丰富血液学产品组合，扩大淋巴瘤治疗的全景，并继续共同努力，促进中国淋巴瘤治疗的标准化。
The drug by Teva was approved in China in 2018, and is the first original product marketed by Teva for the treatment of inert B-cell non-Hodgkin's lymphoma.
Teva的药物于2018年在中国获批，是Teva销售的第一款用于治疗惰性B细胞非霍奇金淋巴瘤的原创产品。
The two companies said that the collaboration will provide a foundation for a combined medication of the drug and two by Roche to create better survival benefits for Chinese lymphoma patients.
两家公司表示，此次合作将为该药物和罗氏公司的两种药物的联合用药奠定基础，为中国淋巴瘤患者创造更好的生存效益。
The five-year survival rate of lymphoma patients in China is 39 percent, compared with about 70 percent in developed countries.
中国淋巴瘤患者的五年生存率为39%，而发达国家约为70%。
The tablet is a new anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used to treat those suffering from non-small cell lung cancer.
该片是一种新型间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂，用于治疗癌症患者。
In recent years, CAR-T cell therapy has achieved great success in the field of lymphoma.
近年来，CAR-T细胞治疗在淋巴瘤领域取得了巨大成功。
未经许可，严禁转发。QQ交流群：688169419